Cargando…

Determination of Optimal Vitamin D Dosage in Children with Cholestasis

BACKGROUND: Vitamin D deficiency in patients with cholestasis is due to impaired intestinal vitamin D absorption, which results from decreased intestinal bile acid concentration. Patients with cholestasis usually do not achieve optimal vitamin D status when a treatment regimen for children without c...

Descripción completa

Detalles Bibliográficos
Autores principales: Chongthavornvasana, Sirada, Lertudomphonwanit, Chatmanee, Mahachoklertwattana, Pat, Korwutthikulrangsri, Manassawee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10283200/
https://www.ncbi.nlm.nih.gov/pubmed/37344793
http://dx.doi.org/10.1186/s12887-023-04113-y
_version_ 1785061258618208256
author Chongthavornvasana, Sirada
Lertudomphonwanit, Chatmanee
Mahachoklertwattana, Pat
Korwutthikulrangsri, Manassawee
author_facet Chongthavornvasana, Sirada
Lertudomphonwanit, Chatmanee
Mahachoklertwattana, Pat
Korwutthikulrangsri, Manassawee
author_sort Chongthavornvasana, Sirada
collection PubMed
description BACKGROUND: Vitamin D deficiency in patients with cholestasis is due to impaired intestinal vitamin D absorption, which results from decreased intestinal bile acid concentration. Patients with cholestasis usually do not achieve optimal vitamin D status when a treatment regimen for children without cholestasis is used. However, data on high-dose vitamin D treatment in patients with cholestasis are limited. METHODS: This study is a prospective study that included pediatric patients with cholestasis (serum direct bilirubin > 1 mg/dL) who had vitamin D deficiency (serum 25-hydroxyvitamin D, 25-OHD, < 20 ng/mL). In Phase 1, single-day oral loading of 300,000 IU (or 600,000 IU if weight ≥ 20 kg) of vitamin D2 was administered, followed by an additional loading if serum 25-OHD < 30 ng/mL, and 4-week continuation of treatment using a vitamin D2 dose calculated based on the increment of 25-OHD after first loading. In Phase 2, oral vitamin D2 (200,000 IU/day) was administered for 12 days, followed by 400,000 IU/day of vitamin D2 orally for another 8 weeks if serum 25-OHD < 30 ng/mL. RESULTS: Phase 1: Seven patients were enrolled. Three out of seven patients had a moderate increase in serum 25-OHD after loading (up to 20.3–27.2 ng/mL). These patients had conditions with partially preserved bile flow. The remaining four patients, who had biliary atresia with failed or no Kasai operation, had low increments of serum 25-OHD. Phase 2: Eleven patients were enrolled. Eight out of 11 patients had a moderate increase in serum 25-OHD after 200,000 IU/day of vitamin D2 for 12 days. Serum 25-OHD continued increasing after administering 400,000 IU/day of vitamin D2 for another 8 weeks, with maximal serum 25-OHD of 15.7–22.8 ng/mL. CONCLUSION: Very high doses of vitamin D2 (200,000 and 400,000 IU/day) partly overcame poor intestinal vitamin D absorption and resulted in moderate increases in serum 25-OHD in pediatric patients with cholestasis, particularly when cholestasis was caused by uncorrectable bile duct obstruction.
format Online
Article
Text
id pubmed-10283200
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102832002023-06-22 Determination of Optimal Vitamin D Dosage in Children with Cholestasis Chongthavornvasana, Sirada Lertudomphonwanit, Chatmanee Mahachoklertwattana, Pat Korwutthikulrangsri, Manassawee BMC Pediatr Research BACKGROUND: Vitamin D deficiency in patients with cholestasis is due to impaired intestinal vitamin D absorption, which results from decreased intestinal bile acid concentration. Patients with cholestasis usually do not achieve optimal vitamin D status when a treatment regimen for children without cholestasis is used. However, data on high-dose vitamin D treatment in patients with cholestasis are limited. METHODS: This study is a prospective study that included pediatric patients with cholestasis (serum direct bilirubin > 1 mg/dL) who had vitamin D deficiency (serum 25-hydroxyvitamin D, 25-OHD, < 20 ng/mL). In Phase 1, single-day oral loading of 300,000 IU (or 600,000 IU if weight ≥ 20 kg) of vitamin D2 was administered, followed by an additional loading if serum 25-OHD < 30 ng/mL, and 4-week continuation of treatment using a vitamin D2 dose calculated based on the increment of 25-OHD after first loading. In Phase 2, oral vitamin D2 (200,000 IU/day) was administered for 12 days, followed by 400,000 IU/day of vitamin D2 orally for another 8 weeks if serum 25-OHD < 30 ng/mL. RESULTS: Phase 1: Seven patients were enrolled. Three out of seven patients had a moderate increase in serum 25-OHD after loading (up to 20.3–27.2 ng/mL). These patients had conditions with partially preserved bile flow. The remaining four patients, who had biliary atresia with failed or no Kasai operation, had low increments of serum 25-OHD. Phase 2: Eleven patients were enrolled. Eight out of 11 patients had a moderate increase in serum 25-OHD after 200,000 IU/day of vitamin D2 for 12 days. Serum 25-OHD continued increasing after administering 400,000 IU/day of vitamin D2 for another 8 weeks, with maximal serum 25-OHD of 15.7–22.8 ng/mL. CONCLUSION: Very high doses of vitamin D2 (200,000 and 400,000 IU/day) partly overcame poor intestinal vitamin D absorption and resulted in moderate increases in serum 25-OHD in pediatric patients with cholestasis, particularly when cholestasis was caused by uncorrectable bile duct obstruction. BioMed Central 2023-06-21 /pmc/articles/PMC10283200/ /pubmed/37344793 http://dx.doi.org/10.1186/s12887-023-04113-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Chongthavornvasana, Sirada
Lertudomphonwanit, Chatmanee
Mahachoklertwattana, Pat
Korwutthikulrangsri, Manassawee
Determination of Optimal Vitamin D Dosage in Children with Cholestasis
title Determination of Optimal Vitamin D Dosage in Children with Cholestasis
title_full Determination of Optimal Vitamin D Dosage in Children with Cholestasis
title_fullStr Determination of Optimal Vitamin D Dosage in Children with Cholestasis
title_full_unstemmed Determination of Optimal Vitamin D Dosage in Children with Cholestasis
title_short Determination of Optimal Vitamin D Dosage in Children with Cholestasis
title_sort determination of optimal vitamin d dosage in children with cholestasis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10283200/
https://www.ncbi.nlm.nih.gov/pubmed/37344793
http://dx.doi.org/10.1186/s12887-023-04113-y
work_keys_str_mv AT chongthavornvasanasirada determinationofoptimalvitaminddosageinchildrenwithcholestasis
AT lertudomphonwanitchatmanee determinationofoptimalvitaminddosageinchildrenwithcholestasis
AT mahachoklertwattanapat determinationofoptimalvitaminddosageinchildrenwithcholestasis
AT korwutthikulrangsrimanassawee determinationofoptimalvitaminddosageinchildrenwithcholestasis